JAJawad Alrawabdeh

Jawad Alrawabdeh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jawad Alrawabdeh has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab

    by Syed Naqvi, Asis Shrestha, Marah Alzubi, Jawad Alrawabdeh, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Carolina Schinke, Samer Al Hadidi

    Talquetamab is an approved therapy for relapsed multiple myeloma. This study examined dysgeusia and weight loss occurrences, alongside investigating symptom reversibility post‐treatment cessation. Dysgeusia was prevalent, persisting in 15% of patients. On average, patients lost 6% of their weight during treatment, with weight loss persisting in about half of the patients post‐discontinuation. Weight loss and dysgeusia are important adverse events to consider while on talquetamab treatment. Extending dose intervals can potentially prevent such adverse events and should be studied in future prospective clinical trials.


  • Open Access

    B‐cell maturation antigen‐based therapies post‐talquetamab in relapsed or refractory multiple myeloma

    by Asis Shrestha, Marah Alzubi, Jawad Alrawabdeh, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Samer Al Hadidi

    Talquetamab recently received approval for relapsed refractory multiple myeloma. However, there is currently no available data on how patients perform with BCMA based agents after progression on talquetamab. Herein, we present the outcome of 10 patients who received BCMA based therapies following talquetamab. The median follow‐up was 9.5 months (range: 6–24 months). The median progression free survival was 5.5 months (range: 1–10 months). Patients had varying grades of cytokine release syndrome and Immune effector cell‐associated neurotoxicity syndrome. Our results suggest that treatment with talquetamab followed by BCMA based therapies is feasible and can be considered as clinically indicated.


  • Open Access

    Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country

    by Abdalla Awidi, Marah Alzu'BI, Nada Odeh, Jawad Alrawabdeh, Muntaser Al Zyoud, Yazan Hamadneh, Hisham Bawa'NEh, Ahmad Magableh, Alaa Alshorman, Feras Al-Fararjeh, et al.

    PURPOSE: Myelodysplastic syndromes (MDS) include a heterogeneous group of clonal bone marrow disorders characterized by ineffective hematopoiesis. They manifest as dysplasia in bone marrow hemopoietic elements associated with peripheral cytopenias with variable risk of AML transformation. PATIENTS AND METHODS: We analyzed retrospectively registry data collected prospectively from patients with primary MDS and patients with MDS/myeloproliferative neoplasm (MPN) in the Jordan University Hospital between January 2007 and September 2021. The registry captured epidemiologic information such as date of diagnosis, age, gender, date of AML transformation, cytogenetics, MDS subtype, risk group according to Revised International Prognostic Scoring System, and survival. The registry also captured baseline ferritin, B12, and lactate dehydrogenase levels. RESULTS: A total of 112 patients with MDS and MDS/MPN were included in the registry. Median age at diagnosis was 59 years. The male-to-female ratio was about 1.2. In a multivariate cox regression model, baseline serum ferritin significantly affected survival as patients with levels exceeding 1,000 μg/L had a risk of death three times higher compared with those with <1,000 μg/L levels ( P < .05). CONCLUSION: To our knowledge, our study is the first comprehensive study examining the epidemiology and prognostic factors in patients with MDS and patients with MDS/MPN in Jordan. Our results show that MDS and MDS/MPN epidemiology in Jordan is different compared with Western countries. Our results also show that baseline serum ferritin levels can be used as a prognostic marker for patients with MDS.


  • The Impact of War Trauma and Housing Environment on Mental Wellbeing of Syrian Refugees in Jordan: A Comparison between In-Camp and Urban Populations

    by Hamza Alduraidi, Feras Al Karmi, Anas Mustafa, Marah Alzu’bI, Nada Odeh, Jawad Alrawabdeh, Muntaser Alzyoud

    The aim of this study is to compare mental wellbeing and levels of post-trauma distress between Syrian refugees who live inside camps and those who live outside camps in Jordan through a survey-based cross-sectional design, where data were collected from 240 adult Syrian refugees in Jordan. The Arabic versions of the Mental Health Continuum Short Form (MHC-SF), and the Impact of Event Scale-Revised (IES-R) were used to quantitatively measure variables through descriptive statistics and multiple comparative analysis tests. Despite having no significant correlation with residence, findings of the MHC-SF showed significance for mental wellbeing with employment status and income. Whereas IES-R showed that camp refugees fared significantly better in terms of trauma effect than urban refugees. It can be concluded that Syrian refugees living inside camps were disadvantaged in terms of mental wellbeing but slightly less affected by war in comparison to those living in urban areas. Improved programs and policies are needed to uplift the mental wellbeing of Syrian refugees in Jordan and to minimize the destructive traumatic effects of the Syrian war on their wellness.


  • Open Access

    Defining an optimal cut-off point for reticulocyte hemoglobin as a marker for iron deficiency anemia: An ROC analysis

    by Marah Alzu’bi, Hisham Bawa’neh, Alaa Alshorman, Jawad Alrawabdeh, Nada Odeh, Yazan Hamadneh, Mai AlAdwan, Mahmoud Odeh, Abdalla Awidi

    Reticulocyte hemoglobin (CHr) is a measure of the amount of hemoglobin in reticulocytes and a marker of cell hemoglobinization. In this study, we aimed to find the optimal cut-off point for reticulocyte hemoglobin to diagnose iron deficiency anemia using multiple methods. A total of 309 patients were included. The median age at diagnosis was 54 years. Most were females (71.2%). 68% had iron deficiency anemia. Patients with IDA had significantly lower levels of CHr compared to those who had non-IDA (p < 0.0001). The optimal cut-off value of CHr for detecting IDA, determined using various methods, was 30.15 pg. This cut-off point had a sensitivity of 87.8% and a specificity of 77.7%. CHr showed a significant positive correlation with hemoglobin, mean corpuscular volume, serum iron, serum ferritin, and transferrin saturation and a significant negative correlation with total iron-binding capacity. CHr levels correlate with most established laboratory tests for IDA. It reliably detects IDA. Our results indicate the importance of CHr in diagnosing IDA, and that CHr should be used more widely in suspected cases of IDA since it is a cheap, fast, and reliable test.